Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot trial will assess the bioequivalence of ondansetron administered as a orally dissolving thin film strip [Zuplenz; MonoSol Rx, Strativa Pharmaceuticals] and as an orally dissolving tablet [Zofran; GlaxoSmithKline] for the prevention of nausea and vomiting induced by moderate or highly emetogenic chemotherapy or radiotherapy.

Next Previous
Trial Profile

A pilot trial will assess the bioequivalence of ondansetron administered as a orally dissolving thin film strip [Zuplenz; MonoSol Rx, Strativa Pharmaceuticals] and as an orally dissolving tablet [Zofran; GlaxoSmithKline] for the prevention of nausea and vomiting induced by moderate or highly emetogenic chemotherapy or radiotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting; Nausea and vomiting; Radiotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Sponsors MonoSol Rx; Par Specialty Pharmaceuticals

    • Most Recent Events

    • 30 Nov 2017 According to a Aquestive Therapeutics media release, MonoSol Rx changed its name to Aquestive Therapeutics
    • 02 Dec 2008 New source identified and integrated (media release from Strativa)
    • 25 Feb 2008 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top